Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracersPET-CTSPECT-CT, and PET-MRI

PET/CT Helps Predict Therapy Effectiveness in Pediatric Brain Tumors

FIGURE: MRI AND PET-MRI FUSION IMAGES OF PATIENTS WITH DIPG. Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of Zr-89-bevacizumab (white arrows), with both PET negative and positive areas within each tumor. Two primary tumors are completely PET negative (Fig. 1C and 1E), while the T2 weighted images show tumor infiltration in the whole pons of both patients. In the middle row, the red arrows represent the areas of contrast enhancement within the tumor. In four out of five primary tumors, the PET-positive area corresponds with the contrast-enhancing area on MRI of the tumors (Fig. 1A, 1B, 1F and 1G). In Fig. 1C, the tumor shows an MRI contrast-enhancing area, while there is no Zr-89-bevacizumab uptake. Fig. 1D shows a PET positive tumor, while no Gd-enhancement is observed on MRI. Credit: Sophie Veldhuijzen van Zanten and Marc Jansen, VU University Medical Center, Amsterdam, The Netherlands.

News | PET-CT | May 02, 2017

May 2, 2017 — In a first-ever molecular drug-imaging study in children, researchers in The Netherlands used whole-...

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017

April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the...

Videos | Nuclear Imaging | April 28, 2017

David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American...

News | Prostate Cancer | April 24, 2017

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...

SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017

April 24, 2017 — The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition...

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017

April 13, 2017 — The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA...

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017

April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...

PET
Feature | Radiology Imaging | April 11, 2017 | By Greg Freiherr
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017

April 5, 2017 — Researchers have used ...

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017

April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization...

Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017

March 31, 2017 — Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance...

News | Radiopharmaceuticals and Tracers | March 29, 2017

March 29, 2017 — Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate)...

lung cancer recurrence, biomarker blood test, CT scans, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study
News | Lung Cancer | March 28, 2017

March 28, 2017 — Results from a prospective clinical trial showed a blood test looking at specific biomarkers was...

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the ...

Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 10, 2017 | Anamika Kumari

Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial...

X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg
News | Radiopharmaceuticals and Tracers | March 09, 2017

March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health...

Navidea, Lymphoseek, North American rights, sale, Cardinal Health
News | Radiopharmaceuticals and Tracers | March 08, 2017

March 8, 2017 — Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to...

PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017

March 3, 2017 — In the featured article of the March 2017 issue of...

Global Medical Imaging Trends

Figure 1: Digital/synthetic reference object (DRO) analysis of the medical imaging market.

Feature | Radiology Imaging | March 02, 2017 | By Infinium Global Research

The emerging markets of Asia-Pacific and Latin America will drive the medical imaging market by more than 5 percent...